12,435 Shares in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Purchased by Tema Etfs LLC

Tema Etfs LLC acquired a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,435 shares of the company’s stock, valued at approximately $266,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its position in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after acquiring an additional 3,828 shares during the period. EntryPoint Capital LLC purchased a new position in shares of Jasper Therapeutics during the fourth quarter worth approximately $223,000. Barclays PLC increased its position in shares of Jasper Therapeutics by 320.7% during the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after acquiring an additional 12,308 shares during the period. JPMorgan Chase & Co. increased its position in shares of Jasper Therapeutics by 239.8% during the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after acquiring an additional 11,567 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Jasper Therapeutics by 12.6% during the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock worth $316,000 after acquiring an additional 1,652 shares during the period. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Stock Up 1.2%

JSPR stock opened at $4.93 on Monday. The stock has a market capitalization of $74.06 million, a P/E ratio of -1.04 and a beta of 2.74. The firm has a 50-day simple moving average of $4.60 and a 200-day simple moving average of $10.86. Jasper Therapeutics, Inc. has a 52 week low of $3.13 and a 52 week high of $26.84.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24). On average, analysts expect that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on JSPR shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. UBS Group reduced their target price on shares of Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Finally, Oppenheimer reduced their target price on shares of Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a research report on Thursday. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics has an average rating of “Buy” and an average price target of $62.22.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.